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Endometriosis is a disease that affects millions of women worldwide and its diagnosis 
is still challenging. Medical history, symptoms together with imaging data may 
address the correct diagnosis, but the gold standard remains laparoscopic assessment 
with histological confirmation. The development of serum markers as diagnostic 
tools for endometriosis may allow a prompt and noninvasive diagnosis. Several serum 
biomarkers have been investigated over the years, but none of these have shown 
a clinical utility and nowadays the more realistic diagnostic biomarker consists in a 
panel of biomarkers. The recent introduction of new technologies such as genomics 
and proteomics may represent the future perspective of endometriosis diagnosis.
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Endometriosis is a disease that affects millions 
of women worldwide, predominantly in repro-
ductive age [1]. Endometriosis is often disabling, 
leading a chronic condition that profoundly 
destabilizes the quality of life of the patient 
with a negative impact on social/personal life 
and with high healthcare costs.
The diagnosis of endometriosis can 
be suspected in women with pelvic pain 
and/or subfertility, although endometrio-
sis may be completely asymptomatic. The 
combination of medical history, symptoms, 
pelvic examination and ultrasonographic 
findings may be useful for a presumptive 
diagnosis. The growing impact of ultra-
sonographic data shows that although the 
ultrasonographic diagnosis of endometri-
oma is relatively certain, with 88% accu-
racy and 90% specificity [2], deep infiltrat-
ing endometriosis remains a heterogeneous 
disease and its diagnosis remains a major 
challenge. Currently, the ultrasonographic 
diagnosis of deep infiltrating endometriosis 
is persistently improving and shows a com-
parable accuracy and specificity of MRI [3]. 
Nevertheless, the gold standard for the 
diagnosis of endometriosis is still the lapa-
roscopic assessment, ideally confirmed by 
histological examination [4].
On these basis, although the several 
improvement in scientific and diagnostic 
knowledge on endometriosis, its diagnosis 
still remains tricky with a delayed time for 
a correct diagnosis, with an average time 
around 6.7 years [5]. It is considered that the 
development of noninvasive diagnostic test 
for endometriosis would have a pronounced 
impact on the patients’ quality of life, antici-
pating endometriosis diagnosis and avoiding 
unnecessary treatment as well as endome-
triosis progression and complications from 
repeated surgery. During the last few years 
the scientific literature widely investigated 
the possible use of specific markers for the 
early diagnosis of endometriosis, but while 
peritoneal markers are too much variable 
under hormonal influence and related to the 
peritoneal fluid amount, the investigation 
of serum markers revealed many interesting 
molecules. The ideal properties of a serum 
biomarker are represented by its specific-
ity and sensitivity, but also by its ability to 
relate to the disease activity allowing disease 
follow-up.
Serum markers for the noninvasive 
diagnosis of endometriosis
Stefano Luisi*,1, Serena 
Pinzauti1, Cristina Regini1  
& Felice Petraglia1
1Obstetrics & Gynecology, Department 
of Molecular & Developmental Medicine, 
University of Siena, Policlinico ‘Le Scotte’ 
Viale Bracci, 53100 Siena, Italy 
*Author for correspondence:  
Tel.: +39 0577 586 641 
Fax: +39 0577 233 454 
stefano.luisi@unisi.it
SPECIAL FOCUS ISSUE y Contemporary Approaches to Endometriosis
For reprint orders, please contact: reprints@futuremedicine.com
604 Womens Health (2015) 11(5) future science group
Review    Luisi, Pinzauti, Regini & Petraglia
Investigated serum markers
Pathogenesis of endometriosis may be considered as 
a multifactorial process that involves predominantly 
hormonal alterations, in terms of estrogen dependence 
and progesterone resistance. Moreover, several and 
recent studies demonstrated a fundamental role of the 
inflammatory response with evasion of the immune 
clearance, of modification in endometrial cell prolif-
eration, attachment and invasion ability and of the 
angiogenetic process. Considering all these possible 
pathogenetic steps, numerous reports tried to recruit 
a reliable serum marker that may be used in the daily 
clinical practice (Table 1).
Tumor antigens: CA-125 & other glycoproteins
Commonly used for the evaluation and diagnosis of 
malignant disease, glycoproteins have largely been eval-
uated as potential diagnostic tools for endometriosis 
diagnosis.
The most consistently studied glycoprotein in 
endometriosis has been CA-125, which, from its char-
acterization in 1981, has been associated to several 
benign and malignant pathologies. CA-125 could be 
identified in patients with cancers of the lung, breast, 
endometrium and gastrointestinal tract, but elevated 
levels have been demonstrated also in benign diseases 
of the liver and gastrointestinal tract, inflammation 
and benign tumors of the ovary and uterus (Table 2). 
Actually, CA-125 evaluation represents the most reli-
able markers for detection of epithelial ovarian cancer, 
showing a significant value as marker of prognosis, 
disease progression and response to chemotherapy. Its 
accuracy has been widely studied also for endometrio-
sis since it is produced by endometrial and mesothelial 
cells and may be secreted into circulation in response 
to inflammation. A complete meta-analysis found 
that serum CA-125 performance in the detection of 
any type of endometriosis was low, but was better for 
the detection of severe endometriosis [6]. Subsequent 
studies confirmed these previous results [7,8], but at the 
same time CA-125 levels have been found to be much 
higher in serum of women with endometrioma [9] or 
dense pelvic adhesions [10] compared with other forms 
of endometriosis.
Finally, the diagnostic accuracy of CA-125 for 
endometriosis is low, considering the most commonly 
employed cut-off values in the literature (35.0 IU/ml). 
Furthermore, normal physiological conditions may 
also modulate CA-125 serum levels causing variations 
in concentrations, as during late secretive phase and 
menstrual phases of menstrual cycle [11].
Nevertheless, nowadays CA-125 remains the only 
serum marker widely used in clinical practice in terms 
of endometriosis diagnosis. To date, CA-125 may be 
proposed more a prognostic marker rather than a diag-
nostic marker, since postoperative CA-125 values have 
been demonstrated to be significantly lower in women 
who achieved a pregnancy and apparently had a com-
plete disease removal [12]. CA-125 levels may also be 
useful in patients’ follow-up after surgical or medical 
treatment or to evaluated disease recurrences [13].
Considering other glycoproteins, CA-19.9 was ini-
tially detected in patients affected by colorectal car-
cinoma, but the evidence that endometriotic tissue 
also expresses CA-19.9 opens several researches on its 
evaluation as serum markers for endometriosis diag-
nosis. However, the results are still contradictory, 
since some studies failed to find any association with 
endometriosis and CA-19.9 serum levels [7], while oth-
ers study reported raised levels of CA-19.9 in patients 
Table 1. Investigated serum markers.





CA-125 – T- and B-cell 
count
–
CA-19.9 – Autoantibodies –
CA-15.3 Activin A Immunoglobulins 
and C3, C4
sFasL
AFP Follistatin NLR E-cadherin
CEA Urocortin IL-6, -8, -2, -4, 
-10, -12, -18, -13, 
-15, -16
ICAM-1
β-2 microglobulin Glycodelin A TNF-α and -β VEGF
Haptoglobin – MPC-1; MIF; 
CXCL10
–
AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; NLR: Neutrophils/lymphocytes ratio; sFasL: Soluble Fas ligand.
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with endometriosis and an association with severe 
stages [14]. Moreover, comparing CA-19.9 and CA-125 
accuracy Harada et al. [14] found that CA-19.9 had 
similar specificity but reduced sensitivity compared 
with CA-125. In a more recent study, CA-125 and 
CA-19.9 serum levels reached similar sensitivities and 
specificities (86–89% and 61–52%, respectively) [15].
Finally, other glycoproteins have been tested during 
the years looking for a significant association with the 
endometriotic disease, such as CA-15.3, CA-72, alpha-
fetoprotein, carcinoembryonic antigen and β-2 micro-
globulin. Recently, new progresses are directed to the 
analysis of serum haptoglobin that has been identified 
as a secretory product of endometriotic lesions. Serum 
levels of haptoglobin-E chain isoforms levels have been 
demonstrated to be significantly higher in women with 
endometriosis than in controls [16].
Growth factors & peptides: activin, follistatin  
& urocortin
Activin A is a member of the TGF-β superfamily and 
it is produced by the healthy endometrium, but also by 
eutopic and ectopic endometrium in endometriosis [17]. 
In physiologic conditions, activin A promotes the pro-
cess of decidualization of endometrium in preparation 
for embryo implantation, allowing uterine receptiv-
ity [18]. An aberrant expression of activin A has been 
observed in the endometrium of women with endome-
triosis and, as consequence, Reis et al. [19] showed only 
a modest increase in serum activin A in women with 
ovarian endometrioma between women with deep 
infiltrating endometriosis and women with the other 
forms of endometriosis.
Follistatin is a glycoprotein involved in the inhibi-
tion of activin A. Its production occurs in a coordi-
nated way with activin A and it is the major regula-
tor of activin bioactivity. Follistatin is abundantly 
expressed in human endometrium and endometri-
otic tissue at all phases of menstrual cycle [20] and by 
antagonizing activin A, it has been shown to inhibit 
stromal cell decidualization. Recently, Florio et al. [21] 
showed a significant increases in serum follistatin lev-
els in women with endometriosis and endometriomas 
compared with controls. The possible role of follistatin 
in the pathogenesis of endometriosis is still unclear, 
but some crucial events implicated in the development 
of the disease, such as endometrial differentiation, 
mesothelial invasion, immune system modulation and 
angiogenesis, are modulated by the activin/follistatin 
system. Serum follistatin was increased in women with 
ovarian endometrioma compared with controls, other 
benign ovarian cysts or nonovarian endometriosis. Fol-
listatin showed a sensitivity of 92% corresponding to 
92% specificity at 1433 pg/ml cut-off. Comparing fol-
listatin and CA-125 accuracy, CA-125 detected only 
44% of endometriomas with 90% specificity, showing 
that follistatin may be considered a potential marker 
of endometrioma, with much higher sensitivity than 
the current marker CA-125. Recently, the same group 
demonstrated that serum follistatin concentrations are 
different in women with endometriosis with higher fol-
listatin levels in peritoneal and ovarian endometriosis 
compared with deep infiltrating endometriosis [19].
Urocortin is a neuropeptide belonging to the cor-
ticotrophin-releasing hormone family, known to be 
expressed in the endometrium [22]. On this basis, serum 
urocortin has been investigated as possible markers for 
endometriosis. Serum levels of urocortin were found to 
be significantly higher in women with endometriomas 
than in women with other benign ovarian cysts, giv-
ing a sensitivity of 88% and specificity of 90%, while 
CA-125 detected only 65% of the cases with the same 
specificity [23].
Glycodelin A is an endometrium-derived protein 
with known angiogenic and immunosuppressive 
effects which could contribute to the development of 
Table 2. Gynecological and nongynecological diseases associated with increased CA-125 serum 
levels.
Gynecological diseases Nongynecological diseases
Benign Malignant Benign Malignant
Endometrioma Epithelial ovarian cancer  Breast cancer
Ovarian teratoma Ovarian dysgerminoma  Lung cancer
Ovarian thecoma Borderline ovarian cancer Peritonitis Liver cancer
Uterine leiomyoma Ovarian granulosa cell 
cancer
Biliary disease Colon cancer
Adenomyosis Endometrial cancer  Pancreatic cancer
Pelvic inflammatory disease Tubal cancer  Mesothelioma
Ectopic pregnancy Cervical cancer   
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endometriosis and endometriosis-related infertility. 
Glycodelin A has been demonstrated to be elevated 
in the sera and in peritoneal fluid of women affected 
by endometriosis, with a sensitivity and specificity as 
a biomarker for ovarian endometriosis of 82.1% and 
78.4% in serum, respectively [24]. Moreover, the com-
bined analysis of IL-6, TNF-α and glycodelin A serum 
concentrations provided a good method of discrimina-
tion between the subjects with endometriosis and the 
controls [25].
Immunological markers: cell populations  
& cytokines
The role of immune system in the pathogenetic process 
of endometriosis is a growing evidence. Consequently, 
various populations of immune cells and their secre-
tions, in term of antibodies and cytokines, have been 
studied to test their utility as biomarkers.
The possible role of T lymphocytes as well as B-cell 
populations have been investigated, although some 
differences have been shown in eutopic endometrium 
and peritoneal fluid, no significant differences have 
been shown in the proportion of serum T and B cells 
in women with and without endometriosis [26,27].
However, the analysis of the autoantibodies has pro-
duced quite a lot of remarkable outcomes. Autoanti-
bodies pattern in women with endometriosis revealed 
significantly increased serum concentrations of B-cell 
levels in women who were positive for antinuclear anti-
bodies (ANA) [28]. Moreover, great attention has been 
focused on the role of serum antiendometrial antibod-
ies as possible cause of infertility in endometriosis; the 
sensitivity and the specificity of serum antiendometrial 
antibody screening have a wide range and their role as 
serum markers is still unconvinced [29]. The increas-
ing evidence that oxidative stress is a key steps in the 
pathogenesis of endometriosis led to analyze oxida-
tively modified lipoproteins and their antibodies and 
this demonstrated that the latter were significantly 
increased in women with endometriosis without any 
correlation with the stage, symptoms or morphologic 
type of the disease [30]. Subsequently, many reports 
focused on the serum evaluation of other autoantibod-
ies, such as antiprogestogen-associated endometrial 
protein antibodies and endometrial glycoproteins, 
antibodies directed against carbonic anhydrase, anti-
bodies to collagen, albumin and IgG, transferrin, but 
all failed to identify a correlation between serum levels 
and endometriosis. Considering total immunoglobu-
lins, they have been assessed in sera of women with 
endometriosis showing no differences with controls, 
even if the medical treatment with danazol exerted a 
significant reduction in all immunoglobulin subtypes 
studied (IgG, IgM and IgA) [31].
Other immunological products have been tested 
with contradictory results. In particular, elevated 
serum levels of C3c and C4 were found in women 
affected by endometriosis [32]. Serum levels of soluble 
HLA class I and II have been demonstrated to be sig-
nificantly lower in women with endometriosis than 
control women [33].
Natural killer (NK) cells have been successfully stud-
ied in peritoneal fluid and eutopic endometrium, show-
ing an altered NK cytotoxicity to endometrial tissue and 
cell cytotoxicity inversely correlated with the stage of the 
disease. However, some studies have failed to identify 
different levels of NK cells in peripheral blood, while 
other studies identify modification of NK subset in sera 
of women with endometriosis comparing controls [34].
Several promising results came from the analysis 
of neutrophils cells population. An interesting recent 
report focused on the concentrations of neutrophils in 
relation to lymphocytes, showing an increase in total 
white blood cell levels, and a particular increase in neu-
trophil levels in endometriosis. Furthermore, the analy-
sis of neutrophils/lymphocytes ratio has been proposed 
as a diagnostic test since it demonstrated sensitivity 
and specificity of 60%. Furthermore, combining neu-
trophils/lymphocytes ratio and CA-125 levels, sensitiv-
ity improved over either test alone, but with slightly 
reduced specificity compared with CA-125 alone. The 
combined marker had a sensitivity of 69.3% and speci-
ficity of 83.9%, showing 13.5% increase in sensitivity 
but 8.9% decrease in specificity when compared with 
serum CA-125 [35].
Considering cytokines, IL-6 and TNF-α represented 
the most investigated types of cytokines. IL-6 is a pro-
inflammatory cytokine involved in T-cell activation, 
B-cell differentiation and secretion of other cytokines 
and its response has shown to be dysregulated in mac-
rophages in patients with endometriosis. Some studies 
have indicated a link between raised serum levels of 
IL-6 in endometriosis, but other studies have shown 
no link, using different cut-off values. In particular, 
Martinez et al. [36] found higher serum levels of IL-6 
in women with Minimal-Mild endometriosis than other 
groups, including Moderate-Severe cases of endometrio-
sis. Using the cut-off level of 25.75 pg/ml, the authors 
described a significant accuracy of IL-6 in detecting 
endometriosis (sensitivity 75.0%, specificity 83.3%), 
proposing IL-6 as a reliable, noninvasive marker of 
minimal and mild endometriosis.
The serum evaluation of other cytokines (IL-2, -4, 
-10, -12, -18, -13, -15, -16) did not produce any addition 
in finding correlation with endometriosis.
TNF-α plays a proinflammatory and proangiogenic 
role in the human endometrium, where it is related to 
physiological endometrial proliferation and shedding. 
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In patients with endometriosis TNF-α raised in peri-
toneal fluid and some studies also showed that higher 
concentrations correlate with the disease stage. Con-
sidering TNF-α as serum marker, the results are still 
uncertain since some reports demonstrated an increase 
in TNF-α levels in women with endometriosis [37], 
while other authors showed no such difference [38]. 
On the contrary, increased levels of serum TGF-β 
have been reported in women with endometriosis and 
their concentrations appeared to correlate with stage 
of disease [39].
Lastly, recent studies evaluated other immuno-
logical factors, such as MPC-1, macrophage migra-
tion inhibitory factor and IFNg-inducible protein-10 
(CXCL10). One study found a significant higher level 
of MCP-1 in early disease stages of endometriosis [39] 
and another demonstrated higher values in more severe 
stages [40]. Serum concentrations of migration inhibi-
tory factor have also been studied as single marker or 
as member of a panel, and serum levels were signifi-
cantly higher in women with endometriosis, especially 
in women with more advanced disease stages [41]. In 
2009, our group focused on the study of CXCL10, 
which is involved in TH1-type immune responses. 
Evaluating serum levels, reduced concentrations were 
found in women with endometriosis compared with 
healthy controls with absence of statistically signifi-
cant differences between women with early endome-
triosis and those with advanced endometriosis was 
found [42].
Other markers: apoptotic, cell adhesion  
& angiogenetic molecules
Accumulating evidence suggests that the endometrial 
cells from women with and without endometriosis 
have fundamental differences and endometrial cells 
from women with endometriosis have enhanced pro-
liferation and increased ability to implant and survive 
in ectopic locations with an impaired sensitivity of 
endometrial tissue to spontaneous apoptosis. In endo-
metriosis, it seems reasonable that an imbalance in 
peritoneal cleaning and excessive receptive mesothe-
lium and cells have the ability to adhere to mesothe-
lial cells of peritoneum, to proliferate and to produce 
neoangiogenesis resulting in the development of active 
endometriotic foci.
The percentage of apoptosis in sloughed endome-
trial cells was greatly reduced among women with 
endometriosis, implying that the number of surviv-
ing cells that enter the peritoneal cavity is greater in 
women who develop endometriosis. The Fas/FasL 
system plays a crucial role in normal tissue homeo-
stasis and pathological conditions since their interac-
tion is essential in inducing apoptosis. Cells expressing 
Fas undergo apoptosis on interaction with other cells 
expressing Fas ligand (sFasL). However, it also exists 
in a soluble form, and women with stages I–II of endo-
metriosis had equivalent serum levels of soluble sFasL 
to controls, but levels were significantly increased in 
women with stages III–IV disease [43].
A variety of factors involved in cell adhesion 
have been studied in endometriosis and both sol-
uble E-cadherin and vascular cell adhesion mol-
ecule-1 VCAM-1 serum levels have been found to 
be elevated in women with endometriosis [44]. The 
most relevant results come from the evaluation of 
intercellular-adhesion molecule-1 (ICAM-1) which 
has been hypothesized to be useful in the diagno-
sis of endometriosis, since ICAM-1 is demonstrated 
to be involved in the implantation and development 
of endometriotic lesions. Many investigators have 
reported a significant increase in serum concentra-
tion of ICAM-1 in patients with endometriosis and 
Somigliana et al. [45] found that women with deep 
peritoneal endometriosis had significantly higher 
concentrations than women without the disease and 
in those with superficial endometriosis. The sensitiv-
ity and specificity of soluble ICAM-1 (sICAM-1) in 
detecting deep peritoneal endometriosis were 19 and 
97%, respectively, concluding that the measurement 
of sICAM-1 may be helpful in specifically identifying 
women with deep infiltrating endometriosis.
Considering neoangiogenesis, VEGF physiologi-
cally induces angiogenesis in endometrial tissue, 
allowing endometrium to repair after menstrua-
tion, but modulates also the characteristics of the 
newly formed vessels. The concentration of VEGF 
is increased in the peritoneal fluid of endometriosis 
patients and its levels raised also in sera of patients 
with endometriomas and other types of endome-
triosis [37]. Moreover, a prospective randomized 
case–control study demonstrated that there was a 
statistically significant difference in serum VEGF 
levels in patients with advanced endometriosis before 
conservative laparoscopic surgery and those without 
endometriosis and after conservative laparoscopic 
surgery, proposing VEGF as biomarkers for advanced 
endometriosis diagnosis [46].
Combined tests
The reported data indicated that a single specific 
serum markers for endometriosis has not been found 
yet and during last year many investigators pro-
posed the use of combined test. Somigliana et al. [7] 
reported the results of the concomitant assessment 
CA-125, CA-19.9 and IL-6 failing in demonstrating 
that it could add significant data in respect to the 
CA-125 test alone. On the contrary, the association 
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of serum and peritoneal fluid markers led to signifi-
cant outcomes, showing that the concomitant dos-
age of serum IL-6 and peritoneal TNF-α provided 
to diagnose women with and without endometriosis 
accurately [47].
On these bases, recently many investigators 
focused their researches on a panel of markers. In 
2010, D’Hooghe et al. [48] evaluated a panel of six 
possible serum markers (IL-6, IL-8, TNF-α, high-
sensitivity C-reactive protein, CA-125 and CA-19.9) 
for the diagnosis of endometriosis and reaching a 
sensitivity and specificity of 100 and 84%, respec-
tively, for moderate-severe endometriosis and a sensi-
tivity and specificity of 87 and 71%, respectively, for 
minimal–mild endometriosis. The same authors con-
tinued their research analyzing a panel of 28 poten-
tial serum markers: the analysis of four biomark-
ers (annexin V, VEGF, CA-125 and sICAM-1/or 
glycodelin) enabled the diagnosis of endometriosis 
undetectable by ultrasound with a sensitivity of 
81–90% and a specificity of 63–81% [49].
Proteomic & genomic: the new perspectives
Proteomic represents the new perspective in the field 
of serum markers and several authors have recently 
attempted to identify specific peptide and protein 
patterns to diagnose endometriosis. Proteomic tech-
nologies provide innovative ways to identify protein 
‘fingerprints’ in blood and from these patterns of 
expression the identification of peptides or proteins 
that are up- or downregulated may allow to assess 
them as possible biomarkers of the disease.
The results are promising for determining high 
accuracy for the diagnosis of endometriosis, in terms 
of sensitivity and specificity, which is confirmed by 
many reports during the last years. In 2008, two dif-
ferent groups detected proteomic patterns in the sera of 
women with endometriosis: Wang et al. [50] identified 
five potential with a sensitivity of 91.7% and a specific-
ity of 90.0%, while Jing et al. [51] based their diagnostic 
algorithm on two protein peaks reporting a sensitivity 
of 87% and specificity of 97%. The same investiga-
tors also found that one of these two peaks was signifi-
cantly altered 1-month after surgery, suggesting that 
it may be a possible marker of disease stage or activ-
ity. More recently, the analysis of 24 different protein 
peaks has been reported, generating a sensitivity and 
specificity of 92 and 75%, respectively [52].
However, the multifactorial pathogenetic process 
of endometriosis also evokes the theory of a family 
inheritance and, as consequence, of a possible identi-
fication of genetic markers of the disease. Gene-based 
technologies include subtractive cDNA hybridiza-
tion and cDNA microarray techniques. Moreover, 
circulating cell-free nucleic acids have been recently 
proposed as reliable markers of several diseases, 
and their evaluation in endometriosis showed that 
the concentration of circulating cell-free nDNA 
in plasma of the patient with endometriosis was 
significantly higher than in the control group [53].
Conclusion
Besides several serum biomarkers have been investi-
gated over the years, with successful and contradic-
tory results, none of these have been clearly shown 
to be of clinical utility (Table 3). Endometriosis is 
heterogeneous and still unknown disease and in its 
presentation may be determinant on the production 
of biomarkers; moreover the differences in studies-
setups (different study and control groups, different 
assay) may lead to patient selection and detection 
bias, altering the overall results.
Future perspective
The more realistic diagnostic biomarker consists 
in a panel of biomarkers, even if the recent studies 
investigating the use of technologies such as genom-
ics and proteomics may represent the future perspec-
tive of endometriosis diagnosis. These techniques 
together with other noninvasive tools, such as ultra-
sound and MRI, may decisively improve the diagno-
sis of endometriosis and patients’ quality of life, as a 
consequence.
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Table 3. Sensitivity and specificity of new 
reliable serum markers.
Markers Sensitivity (%) Specificity (%)
Activin A 33 90
Follistatin 92 92
Urocortin 88 90
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